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Falsely Elevated Thyroglobulin in a Patient with Thyroid Cancer and Rheumatoid Arthritis after
Adalimumab Therapy
Archana Purushothaman, Nicholas Lintel, Kaitlin Brau, Whitney Goldner

Mentor: Whitney Goldner
Program: Diabetes, Endocrinology, and
Metabolism
Introduction: Thyroglobulin (TG) elevation
is used as a tumor marker for evidence
of recurrence or metastatic disease of
thyroid carcinoma.TG assays are usually
immunoassays which are subject to a number
of interferences.
Case: We report a middle-aged patient with
rheumatoid arthritis (RA) and Follicular
Variant of Papillary Thyroid Carcinoma,
AJCC 7, stage T2N0M0, status post total
thyroidectomy and RAI ablation, with ATA
excellent response to therapy. Ten years after

diagnosis, the patient presented with sudden
elevation in TG of 111 ng/mL. On repeat
testing, TG ranged from 111-300 ng/mL with
undetectable TG ab. Imaging did not reveal
evidence of recurrent disease. On further
investigation, the patient reported starting
adalimumab for rheumatoid arthritis one-year
prior. Tenfold dilution of the sample showed
a decrease in TG from 300 to 47 ng/mL in a
non-linear manner, suggestive of interference.
The serum was treated with blocking agents
and the TG decreased to 2.7 ng/mL suggesting
the presence of HAMA. TG testing via mass
spectrometry was undetectable.

abs that interact with assay abs. In 2-site
immunometric “sandwich complex” assays,
they often generate false-positive results.
Those with RA are at risk of interference from
RF or they can generate abs from exposure
to immunotherapies that use chimeric abs.
Adalimumab is a fully human monoclonal
ab, so not expected to result in production of
HAMA. The assay interference in this case
is likely due to either RF or HAMA from an
unknown source. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.065

Conclusion: Heterophilic abs like
Rheumatoid Factor (RF) or HAMA are human

A Rare Case of Lung Cancer Metastasis to Thyroid
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Background: Most common tumors in
thyroid are well differentiated thyroid
malignancies (Papillary and Follicular).
Metastasis to thyroid gland are rare despite
thyroid being a very vascular organ. Lung
cancer commonly metastasize to liver,
adrenals, brain and bones. Here we present
a rare case of non-small cell lung cancer
metastasis to a previously benign thyroid
nodule.
Methods: An elderly patient was followed at
the Endocrine clinic for multinodular goiter
for several years. The patient had biopsy of
these nodules multiple times in the past and
have been benign. In 2016, the patient was

diagnosed with large cell lung cancer and was
treated with resection and chemotherapy.
In 2017, an ultrasound showed increase in
size of the right thyroid nodule. The patient
underwent FNA and it showed indeterminate
results with rare atypical cells suspicious of
carcinoma. It was sent for molecular testing
and it was negative for thyroid malignancy.
Results: The slides were reviewed by the
pathologist again and compared to the
prior lung tumor specimens and it showed
similar features to the lung carcinoma. CT
scan showed prominent thyroid mass with
enlarged paratracheal lymph node. The
patient underwent total thyroidectomy and
lymph node removal for definitive diagnosis.
Pathology confirmed non-small cell lung
carcinoma.

Conclusions: In a patient with another known
primary cancer, metastasis to thyroid should
be considered in the differential of thyroid
nodule. Imaging alone will not differentiate
between primary and secondary thyroid
malignancies. Molecular markers for thyroid
cancer if negative do not rule out metastasis
from another primary malignancy. FNAC
with histochemistry and comparing to primary
tumor help make the diagnosis. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.066

Cachexia Index: A Marker for Survival in Pancreatic Cancer?
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Introduction: The incidence of pancreatic
cancer is on the rise and continues to have a
poor overall survival despite advancement in
treatment strategies. The effect of sarcopenia
on the prognosis of patients with pancreatic
cancer is unknown.
Methods: We performed a single-center
retrospective study at our institution by
measuring muscle mass among patients with
pancreatic cancer from CT scan at initial
diagnosis and at 8 weeks post-treatment.
The results were stratified based on the
57

percentage of muscle loss (<10% and >10%)
to determine whether sarcopenia impacted
outcomes primarily, overall survival (OS) and
progression-free survival (PFS).
Results: This retrospective study included
162 patients from the University of Nebraska
medical center diagnosed between 2009 and
2017 with stage I-IV pancreatic cancer. We
calculated hazard ratios (HRs) to evaluate
the associations of overall survival with
sarcopenia. There is a significant association
between improved OS and PFS among those
with less intensive reduction in muscle mass
(p=0.038, p=0.027 respectively). However,
no significant association of BMI loss with
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overall mortality on either OS or PFS (p=0.80,
p=0.65).
Conclusion: The presence of sarcopenia may
be a predictor of prognosis among patients
with pancreatic cancer. A better understanding
of the molecular mechanisms of sarcopenia
might help improve survival outcomes in
pancreatic cancer. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.067
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